Profile cover photo
Profile photo
Institute for Medical Education & Research, Inc.
148 followers -
A leading provier of high-quality state-of-the-art continuing education for oncology professionals
A leading provier of high-quality state-of-the-art continuing education for oncology professionals

148 followers
About
Institute for Medical Education & Research, Inc.'s posts

Post has attachment
Target Audience

This activity is intended for oncologists, nurses, and pharmacists in cancer care.
 

Purpose

The goal for this activity is to educate the multidisciplinary care team – oncologists, nurses, and pharmacists –  on rapidly evolving immunologic treatment approaches.
 

Activity Overview

Advances in basic immunology have led to an improved understanding of the interactions between the immune system and tumors, generating renewed interest in novel immunologic approaches to the treatment of cancer. Indeed, there have been multiple FDA approvals of immunologic agents in recent years and there are many ongoing trials of novel immunotherapies in lung cancer, colorectal cancer, and other tumor types.

In this series of half-day conferences, leading oncologists will provide an overview of immune system–cancer interactions, the safety and efficacy of recently approved immunologic agents for the treatment of melanoma and prostate cancer, the latest data from ongoing trials in non-small cell lung cancer, colorectal cancer, and others, and the management of immune-related adverse events (IRAEs). These sessions will include case studies to stimulate interactive discussion of real-world treatment scenarios. 

Learning Objectives

Upon completion of this activity, participants should be better able to:

Describe the biological foundations of immunotherapy approaches to the treatment of cancer
Identify the mechanisms of action of immuno-oncologic agents such as vaccines and immune system-modulating antibodies
Evaluate new safety and efficacy data on recently approved and emerging immunotherapies across tumor types
Describe how new immunotherapies are integrated into existing treatment evidence-based guidelines
Identify ongoing research efforts in immuno-oncology including how to appropriately select patients who would be candidates for clinical trials

Post has attachment
Immuno-Oncology: A Colliquium on the State of the Science for Oncology Clinicians

Saturday, September 8, 2012
8:00 AM—12:15 PM EST

Doubletree Metropolitan Hotel
Metro 1 Ballroom
569 Lexington Avenue
New York, NY 10022

REGISTER HERE --- http://bit.ly/R45TJR
Photo

Post has attachment
Register now for our FREE CML 1/2 day symposium! "The Future of Cancer Care: Lessons Learned in Chronic Myeloid Leukemia" http://imeronline.com/776_CML_Pittsburgh_Conference
Photo

Post has attachment

Post has attachment
Gastric cancer is diagnosed in nearly 1 million people globally each year and is responsible for 740,000 deaths, making it the second leading cause of cancer death in the world. According to the American Cancer Society, more than 21,000 people in the United States were diagnosed with gastric cancer and more than 10,500 died from the disease in 2010. Read the full article by our medical director Dr. Libia Scheller!

Post has attachment

Post has attachment

Post has attachment
Photo

Post has attachment
PhotoPhotoPhotoPhotoPhoto
IMER Content (6 photos)
6 Photos - View album
Wait while more posts are being loaded